PatientsVille.com Logo


Ethambutol Medical Research Studies

Up-to-date List of Ethambutol Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ethambutol Medical Research Studies

Rank Status Study
1 Not yet recruiting Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
Condition: Pulmonary Tuberculosis Without Resistance to Rifampicin
Interventions: Drug: Linezolid;   Drug: Ethambutol
Outcome Measures: Sputum culture conversion rate on liquid media;   Sputum culture conversion rate on solid media;   Time to sputum culture conversion (liquid and solid media);   Cure rate;   Treatment success rate
2 Recruiting Improving Retreatment Success (IMPRESS)
Condition: Recurrent Tuberculosis
Intervention: Drug: moxifloxacin
Outcome Measures: A moxifloxacin-containing regimen, substituting moxifloxacin for Ethambutol, is superior to a control regimen in improving treatment outcomes;   1.Time to culture-conversion of the moxifloxacin regimen and the Ethambutol regimen using data from 2-, 4-, 6-, and 8-week cultures;   Compare the proportion of patients with any Grade 3 or 4 adverse reactions;   Compare adverse events and 2-month culture conversion rates among HIV-infected patients vs. HIV-uninfected patients;   Compare the rates of treatment failure and recurrence of the intervention and control arm.
Condition: Tuberculosis
Intervention: Drug: intravenous administration of 1st line TB drugs, to compare with oral regimens (isoniazid, rifampin, and Ethambutol)
Outcome Measures: pharmacokinetics;   pharmacokinetics (AUC0-8, Cmax, and Tmax) of HRZE;   To evaluate adverse events of HRZE, week 1 and 8 - while taking food or not
4 Not yet recruiting Early Bactericidal Activity (EBA) Study of Tuberculosis Regimens With and Without INH and Moxifloxacin
Condition: Tuberculosis
Interventions: Drug: Rifampicin;   Drug: Isoniazid;   Drug: Pyrazinamide;   Drug: Ethambutol;   Drug: Moxifloxacin
Outcome Measure: Daily decrease in log10 CFU/ml sputum between day 2 and 14 since study treatment initiation
5 Not yet recruiting Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis
Condition: Sarcoidosis; Antimycobacterial Therapy;
Interventions: Drug: Levofloxacin;   Drug: Ethambutol;   Drug: Azithromycin;   Drug: Rifampin;   Drug: Placebo
Outcome Measures: Determine the effect of CLEAR therapy versus placebo on the change in percent predicted absolute forced vital capacity (FVC) in participants with pulmonary sarcoidosis, comparing baseline with performance after completion of 16 weeks of therapy.;   Radiographic improvement in sarcoidosis lung disease by frontal chest x-ray .;   Change in 6 minute walk distance, oxygen saturation and level of dyspnea;   Change in the Saint George's Respiratory Questionnaire (SGRQ; King's Sarcoidosis Questionnaire (KSQ) for the assessment of health status; The Fatigue Assessment Scale (FAS).;   Safety profile of regimen as evidenced by adverse events and abnormal lab values, tolerability and toxicity of the treatment regimen including comparison of reported adverse events and abnormal laboratory values compared to placebo.;   Change in FEV1;   Failure of standard Therapy
6 Recruiting Latency in Pulmonary Tuberculosis
Condition: Pulmonary Tuberculosis
Intervention: Drug: Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol
Outcome Measures: The immune response to crude antigens - PPD and CFA and defined antigens - ESAT-6 and CFP-10 as well as positive controls- SEB and anti-CD3.;   Determining the correlation of increase in regulatory factors with the development of relapse in treated TB patients.
7 Not yet recruiting Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3
Condition: HIV-1 Infection
Interventions: Device: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray;   Drug: ART (Atripla, Truvada, Efavirenz, Combivir);   Drug: Rifampin, isoniazid, pyrazinamide, Ethambutol
Outcome Measures: All-cause mortality and incidence of invasive bacterial infections;   Incidence of confirmed/probable/possible TB;   Incidence of grade 3 or 4 adverse events
8 Recruiting REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
Condition: HIV Infection
Interventions: Drug: Atripla (r);   Drug: Efavirenz;   Drug: Truvada;   Drug: Rifampin/isoniazid/pyrazinamide/Ethambutol FDC;   Drug: Rifampin/isoniazid FDC
Outcome Measures: Survival status at 24 weeks post randomization;   Time from randomization to death;   Time from randomization to AIDS progression (defined as the identification of a new World Health Organization (WHO) stage 3 or 4 condition);   AIDS-free survival status at 24 and 48 weeks (cumulative);   HIV-1 RNA level (<400 vs. ≥400 copies/mL) at weeks 4, 24, and 48;   Safety and tolerability status at 24 and 48 weeks (cumulative);   Time to initiation of TB treatment;   CD4+ cell count and change from baseline at weeks 4, 24, and 48;   TB diagnosis per current ACTG Diagnosis Appendix
9 Not yet recruiting Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes
Condition: AIDS With Tuberculosis
Intervention: Drug: Rifampicin, Isoniazid, Ethambutol, Pyrazinamide
Outcome Measures: clinical outcome;   Cmax;   Number of adverse events;   ART trough levels;   Isoniazid Cmax
10 Recruiting Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
Conditions: HIV Infection;   Pulmonary TB
Intervention: Drug: ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)
Outcome Measures: Development of bacteriological failure & Emergence of acquired rifampicin resistance;   Unfavorable responses: clinical failures, recurrences and death due to TB during treatment and follow-up;   TEADR's between the groups;   Incidence of Immune Reconstitution Syndrome among the groups
11 Recruiting Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease
Condition: Chronic Liver Disease With Tuberclosis
Interventions: Drug: 2HRZE/4HR;   Drug: 2HRLE/4HR;   Drug: 9HLE;   Drug: 9RLE
Outcome Measures: Successful completion of modified ATT (ANTI TUBERCULAR TREATMENT) regimen.;   Worsening of CTP (CHILD TURCOTTE PUGH) score to ≥10 for patients with compensated cirrhosis,;   Failure to re-institute the assigned ATT (ANTI TUBERCULAR TREATMENT) regimen after development of an episode of hepatotoxicity. (I.e. second episode of hepatotoxicity.;   Survival
12 Recruiting Pharmacokinetics of Anti-TB Drugs in HIV/TB Co-infected Children in Ghana
Conditions: Tuberculosis;   HIV
Outcome Measures: Descriptive statistics of PK parameters (Cmax, Tmax, AUC0-8h) of rifampin, isoniazid, pyrazinamide and Ethambutol in children with TB with and without HIV coinfection;   Frequency of liver enzymes elevations compare to baseline, skin rashes, nausea, vomiting and treatment discontinuation or modifications due to drug side effects in children with TB with and without HIV coinfection;   Relationship between genetic polymorphisms of N-acetyltransferase type 2 (NAT2) enzyme and isoniazid plasma Cmax and AUC in Ghanaian children with TB with and without HIV;   Relationship between genetic polymorphisms of SLCO1B1 transporter and rifampin plasma Cmax and AUC in Ghanaian children with TB with and without HIV;   Relationship between plasma Cmax and AUC of isoniazid, rifampin, Ethambutol and pyrazinamide at week 4 of therapy and frequency of anti-TB treatment discontinuation or modification;   Relationship between NAT2 acelator status, SLCO1B1 genotype status and anti-TB treatment completion, discontinuation or modification;   Relationship between body weight, gender, nutritional status and plasma Cmax and AUC of isoniazid, rifampin, Ethambutol and pyrazinamide in Ghanaian children with TB with and without HIV
13 Recruiting Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in HIV
Conditions: HIV Infection;   Tuberculosis
Interventions: Drug: Lopinavir/Ritonavir;   Drug: Raltegravir;   Drug: Isoniazid;   Drug: Pyridoxine;   Drug: Pyrazinamide;   Drug: Ethambutol;   Drug: Rifabutin;   Drug: Rifampin
Outcome Measures: Percent of participants whose HIV viral load was less than 400 copies/mL (Arm B vs Arm A and Arm B vs Arm C);   Percent of participants who experienced mycobacterial culture conversion (Arm B vs Arm A and Arm B vs Arm C);   Percent of participants who experienced TB treatment failure (Arm B vs Arm A and Arm B vs Arm C);   Percent of participants who experienced TB relapse/recurrence (Arm B vs Arm A and Arm B vs Arm C);   Percent of participants whose HIV viral load was less than 50 copies/mL (Arm B vs Arm A and Arm B vs Arm C);   Percent of participants whose HIV viral load was less than 400 copies/mL (Arm A vs Arm C);   Percent of participants whose HIV viral load was less than 50 copies/mL (Arm A vs Arm C);   Percent of participants reporting a grade 3 or 4 adverse event or laboratory abnormality recurrence;   Percent of participants who interrupted or discontinued at least one HIV drug due to toxicity;   Percent of participants who interrupted or discontinued at least one TB drug due to toxicity;   Percent of participants who experienced HIV virologic failure;   Percent of participants who experienced TB IRIS;   CD4 count change from randomization;   Percent of participants who experienced a new AIDS-defining illness;   Percent of participants who experienced death;   Percent of participants who experienced a new AIDS-defining illness or death;   Time to HIV virologic failure
14 Recruiting Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)
Conditions: Tuberculosis;   HIV
Interventions: Drug: 8 hourly LPV/r during TB treatment;   Drug: Nevirapine;   Drug: Lopinavir/Ritonavir
Outcome Measure: Area under the concentration time curve (AUC) for rifampicin, isoniazid, pyrazinamide, Ethambutol, lopinavir and nevirapine
15 Unknown  Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou
Condition: Pulmonary Tuberculosis
Interventions: Other: Directly Observed Therapy (DOTS) plus;   Other: Directly Observed Therapy (DOTS)
Outcome Measures: combined treatment failure/ relapse (unfavourable outcome) among rifampicin resistant group.;   combined treatment failure/ relapse (unfavourable outcome) among rifampicin resistant group, MDR-TB cases and all retreatment cases;
16 Recruiting Treatment of Mycobacterium Xenopi Pulmonary Infection
Condition: Atypical; Mycobacterium, Pulmonary, Tuberculous
Interventions: Drug: Clarithromycin;   Drug: Moxifloxacin
Outcome Measures: Sputum conversion at 6 months under three antibiotics treatment (Rifampin, Ethambutol and a third drug clarithromycin or moxifloxacin);   Sputum conversion at 3, 6, 9 and 12 months of treatment in the two different arms (clarithromycin containing regimen versus moxifloxacin containing regimen;   Clinical and radiological outcome after 3, 6 and 12 months of treatment according to the treatment arm;   Mortality after 12 months of treatment in the two compared regimen;   Gastrointestinal toxicity and hematotoxicity after 1- 3- 6- 9- 12- months of treatment
17 Recruiting Effect of Prophylactic Use of Silymarin on Hepatotoxicity Induced by Anti-tuberculosis Drugs
Condition: Tuberculosis
Interventions: Drug: Silymarin;   Drug: Placebo
Outcome Measures: incidence of hepatotoxicity;   incidence of hepatotoxicity by genotypic variants
18 Unknown  Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Conditions: Tuberculosis;   Tuberculosis, Pulmonary;   Early Gastric Cancer
Outcome Measures: The change in the maximum concentration (Cmax) of first-line TB drugs;   The effects of pharmacokinetics on responses of pulmonary TB to anti-TB drug
19 Recruiting Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
Condition: HIV Infections
Interventions: Drug: Current ARV medications;   Drug: Current TB medications;   Drug: Current hormonal contraceptive medications
Outcome Measures: Drug parameter: Area under the curve from 0 to 12 hours (AUC 0-12);   Drug parameter: Area under the curve from 0 to 24 hours (AUC 0-24);   Drug parameter: Maximum concentration (Cmax);   Drug parameter: Pre-dose concentration (Cdose);   Drug parameter: Minimum concentration (Cmin);   Drug parameter: Time after administration of drug when maximum plasma concentration is reached (Tmax);   Drug parameter: Clearance over systemic availability (Cl/F);   Drug parameter: Volume of distribution over systemic availability (V/F);   Drug parameter: Half-life (t1/2);   ARV concentrations in vaginal secretions;   ARV concentrations in plasma;   For contraceptives: plasma concentration;   Ratio of cord blood concentration to maternal blood concentration;   Ratio of unbound/total drug concentrations;   Rate of detection of study drugs in vaginal secretions;   Ratio of vaginal drug concentrations to simultaneous blood concentrations;   Rate of detection of HIV RNA/DNA in vaginal secretions and comparison to level in blood;   ARV exposure (as measured by area under the curve or other PK parameters) during pregnancy and postpartum according to genotype;   Adverse events of grade 3 or higher;   Infant neurological events of grade 1 or higher;   Adverse pregnancy outcome: preterm birth;   Adverse pregnancy outcome: low birth weight;   Adverse pregnancy outcome: fetal demise;   Adverse pregnancy outcome: congenital anomalies;   Infant HIV infection status
20 Not yet recruiting Optimization of the TB Treatment Regimen Cascade
Condition: Tuberculose
Interventions: Drug: double rimfampicin;   Drug: Standard TB treatment
Outcome Measures: Tuberculose treatment outcome;   Serious Adverse Events and Liver toxicity;   low-level rifampicin resistant TB adverse treatment outcomes;   effectiveness of standard auramine;   assess the negative predictive value of conversion for relapse;   estimate the proportion of acquired rifampicin resistance among failures and relapses

These studies may lead to new treatments and are adding insight into Ethambutol etiology and treatment.

A major focus of Ethambutol research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Ethambutol